Does Viagra cause gynaecomastia? It is a reasonable concern for men taking sildenafil, yet the evidence suggests no confirmed causal link exists. Viagra (sildenafil), a PDE5 inhibitor widely used in the UK for erectile dysfunction, does not directly alter sex hormone levels or possess oestrogenic properties. Whilst gynaecomastia has appeared in post-marketing reports, its frequency is listed as 'not known' in the UK Summary of Product Characteristics. This article explores the pharmacology, known side effects, other recognised causes of gynaecomastia, and when to seek medical advice.

Can Viagra Cause Gynaecomastia?

There is no established pharmacological mechanism or confirmed causal link between Viagra (sildenafil) and gynaecomastia; it does not alter sex hormones or have oestrogenic properties.

Viagra (sildenafil) is a phosphodiesterase type 5 (PDE5) inhibitor widely prescribed in the UK for erectile dysfunction. It is also available under the brand name Revatio for pulmonary arterial hypertension (PAH), where the standard adult dose is 20 mg three times daily — a different dosing regimen from the erectile dysfunction indication. Sildenafil works by inhibiting the PDE5 enzyme, leading to smooth muscle relaxation and increased blood flow to specific tissues. Understanding whether it can cause gynaecomastia — the benign enlargement of glandular breast tissue in males — requires a careful look at both its pharmacology and the available evidence.

Gynaecomastia occurs when there is an imbalance between oestrogen and androgen activity in breast tissue. Certain medicines can disrupt this hormonal balance directly or indirectly, triggering glandular proliferation. Sildenafil does not directly alter sex hormone levels, nor does it have known oestrogenic or anti-androgenic properties. On this basis, there is no established pharmacological mechanism by which Viagra would be expected to cause gynaecomastia.

Gynaecomastia has appeared in post-marketing reports for sildenafil; however, the frequency is listed as 'not known' (cannot be estimated from available data) in the UK Summary of Product Characteristics (SmPC), and a definitive causal link has not been confirmed. It is important to note that many men taking Viagra also have underlying conditions — such as hypogonadism, liver disease, or obesity — or take concomitant medicines that are themselves known causes of gynaecomastia. This makes it difficult to attribute breast tissue changes to sildenafil alone, and there is no confirmed causal link between standard Viagra use and clinically significant gynaecomastia. If you notice breast tissue changes while taking sildenafil, discuss them with your GP or prescriber rather than stopping the medicine without advice.

Known Side Effects of Viagra Reported in the UK

The most common side effects of sildenafil are vasodilatory in origin, including headache, flushing, and dyspepsia; gynaecomastia is listed at unknown frequency in post-marketing data.

The UK SmPC and MHRA-approved patient information leaflet (PIL) for sildenafil outline a well-characterised side-effect profile, most of which relate directly to its vasodilatory mechanism of action. The most commonly reported adverse effects include:

• Headache — due to cerebral vasodilation

• Flushing — caused by peripheral vasodilation

• Dyspepsia and nasal congestion — also vasodilatory in origin

• Visual disturbances — including altered colour perception (a blue-green tinge), blurred vision, or increased light sensitivity, related to mild PDE6 inhibition in the retina

• Dizziness and hypotension — particularly relevant in the context of interactions (see below)

Less commonly, users may experience palpitations, nausea, or a rash. Serious but rare adverse effects include:

• Priapism — a prolonged, painful erection lasting more than four hours, requiring prompt medical attention

• Sudden hearing loss — seek urgent medical advice if this occurs

• Non-arteritic anterior ischaemic optic neuropathy (NAION) — a rare cause of sudden, painless loss of vision in one or both eyes; stop sildenafil and seek immediate medical attention if sudden visual loss occurs

• Severe hypotension — particularly if sildenafil is taken with contraindicated or interacting medicines

Important safety information — contraindications and interactions: Sildenafil is contraindicated with nitrates in any form (including glyceryl trinitrate, isosorbide mononitrate, and amyl nitrite, sometimes called 'poppers') and with riociguat, due to the risk of severe, potentially life-threatening hypotension. Do not take sildenafil if you use any nitrate medicine or riociguat. Caution is also required with alpha-blockers (such as doxazosin or tamsulosin), which can cause additive blood pressure lowering; dose timing and review with a prescriber are advisable. Potent CYP3A4 inhibitors — including certain antibiotics (e.g., erythromycin), antifungals (e.g., ketoconazole), and HIV protease inhibitors — can significantly increase sildenafil plasma levels and may require dose adjustment or avoidance.

In terms of breast-related changes, gynaecomastia appears in post-marketing reports as an adverse event of unknown frequency and is not considered a clinically prominent or well-established side effect of sildenafil. The MHRA Yellow Card scheme allows patients and healthcare professionals to report suspected adverse drug reactions (yellowcard.mhra.gov.uk). Any new or unexpected physical change — including breast tissue enlargement — occurring after starting Viagra should be reported through this system and discussed with your prescriber.

Other Medicines and Causes Linked to Gynaecomastia

Medicines with well-established links to gynaecomastia include spironolactone, finasteride, anti-androgens, and digoxin; non-drug causes include hypogonadism, liver disease, and obesity.

When a man presents with gynaecomastia, it is essential to consider the full clinical picture before attributing the change to any single medicine. Gynaecomastia is a relatively common condition — affecting up to 65% of adolescent males transiently and a significant proportion of older men — and has numerous well-documented causes beyond medication use.

Medicines with a well-established or recognised link to gynaecomastia include:

• Spironolactone — an aldosterone antagonist with anti-androgenic properties, commonly used in heart failure and hypertension

• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) — used for benign prostatic hyperplasia and male-pattern hair loss

• Anti-androgens (e.g., bicalutamide, cyproterone acetate) — used in prostate cancer treatment

• Anabolic steroids and testosterone therapy — through aromatisation to oestrogen

• Cimetidine — an older H2-receptor antagonist

• Certain antipsychotics (e.g., haloperidol, risperidone) — via hyperprolactinaemia; the association with antidepressants is less consistent and varies by agent

• Digoxin — which has weak oestrogenic-like activity

• Ketoconazole — which inhibits androgen synthesis

• Efavirenz — an antiretroviral associated with gynaecomastia in some patients

Non-pharmacological causes include hypogonadism, hyperthyroidism, chronic liver disease (which impairs oestrogen metabolism), chronic kidney disease, and obesity (which increases peripheral aromatisation of androgens to oestrogens). Recreational drug use — including cannabis, heroin, and anabolic steroids — is also a recognised contributing factor.

In many cases, gynaecomastia is idiopathic, meaning no clear cause is identified. A thorough medication review, including over-the-counter products and supplements, is a critical first step in assessment. NICE CKS guidance on gynaecomastia and standard UK primary care practice recommend a structured history, examination, and appropriate investigations, which typically include: morning serum testosterone, LH, FSH, oestradiol, prolactin, serum hCG, liver function tests, TSH, and renal function. Testicular examination should be performed, and testicular ultrasound considered if hCG is elevated or there are abnormal testicular findings, to exclude a germ cell tumour. These investigations help identify any underlying hormonal or systemic cause before attributing changes to a specific drug.

When to Speak to a GP About Breast Tissue Changes

Men should contact their GP promptly if they notice a hard, unilateral, or irregular breast lump, nipple discharge, or skin changes, as male breast cancer must be excluded.

Any new or unexplained change in breast tissue in a man warrants medical evaluation, regardless of whether it is thought to be related to a medicine. While gynaecomastia is usually benign, it is important to distinguish it from other conditions — most critically, male breast cancer, which, although rare, accounts for approximately 1% of all breast cancer diagnoses in the UK (NHS).

You should contact your GP promptly if you notice:

• A firm or hard lump beneath the nipple or in the breast tissue

• A lump that is unilateral (one-sided), irregular in shape, or fixed to surrounding tissue

• Nipple discharge, particularly if bloodstained; men aged 50 or over with unilateral nipple discharge should be considered for urgent referral

• Skin changes over the breast, such as dimpling, puckering, or redness

• Swelling of the lymph nodes in the armpit

• Breast pain that is persistent, worsening, or associated with other symptoms

Gynaecomastia typically presents as a soft, rubbery, disc-like swelling centred beneath the nipple, often bilateral, and may be mildly tender. This is distinct from pseudogynaecomastia (fatty tissue deposition without glandular proliferation), which is common in overweight men and does not require the same level of investigation.

In line with NICE NG12 (Suspected cancer: recognition and referral), men with a unilateral, hard, or irregular breast lump should be referred urgently via the two-week-wait pathway for suspected cancer. Your GP will take a full history — including all current medicines, supplements, and lifestyle factors — and may arrange blood tests or imaging to clarify the cause. Do not delay seeking advice; early assessment ensures appropriate management and peace of mind.

Seeking Advice From a UK Pharmacist or Prescriber

A UK pharmacist or prescriber can review medicines for interactions, assess breast symptoms, and advise whether a GP referral is needed; do not stop prescribed sildenafil without medical advice.

If you are taking Viagra (sildenafil) and have noticed changes in your breast tissue, or if you are concerned about potential side effects before starting treatment, speaking to a pharmacist or prescriber is a sensible and accessible first step. In the UK, sildenafil is available both on NHS prescription and as a Pharmacy (P) medicine — Viagra Connect 50 mg — which is supplied by a pharmacist following a clinical assessment to ensure it is appropriate and safe for you. This is not a simple over-the-counter purchase; the pharmacist will ask about your health and medicines before supplying it.

Experiencing these side effects? Our pharmacists can help you navigate them →

A community pharmacist is well placed to:

• Carry out a clinical assessment before supplying Viagra Connect, including checking for contraindications and interactions

• Review your current medicines for any known interactions or drugs associated with gynaecomastia

• Advise on whether your symptoms warrant a GP appointment

• Help you report a suspected adverse drug reaction via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)

• Provide reassurance and signpost you to appropriate services

If sildenafil was prescribed by a GP or specialist, contact your prescriber directly to discuss any new symptoms. Do not stop taking a prescribed medicine without medical advice, as this may have implications for your underlying condition. Your prescriber can assess whether the breast changes are likely to be medicine-related, refer you for further investigation if needed, or consider an alternative treatment if appropriate.

For men obtaining Viagra Connect from a pharmacy, it remains important to disclose all other medicines and health conditions to the dispensing pharmacist. Key safety points include: sildenafil is contraindicated with nitrates (including amyl nitrite) and riociguat; caution is required with alpha-blockers; and certain medicines that inhibit the CYP3A4 enzyme (such as erythromycin, ketoconazole, or HIV protease inhibitors) can increase sildenafil levels and may require dose adjustment or avoidance. Open, honest conversations with your healthcare team are the most effective way to manage both your sexual health and any unexpected physical changes safely.

Frequently Asked Questions